Currently, there are 54.94M common shares owned by the public and among those 54.83M shares have been available to trade.
The company’s stock has a 5-day price change of 10.44% and 18.41% over the past three months. CRMD shares are trading 65.96% year to date (YTD), with the 12-month market performance up to 52.94% higher. It has a 12-month low price of $2.57 and touched a high of $7.00 over the same period. CRMD has an average intraday trading volume of 579.29K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 29.33%, 34.65%, and 46.80% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of CorMedix Inc (NASDAQ: CRMD) shares accounts for 30.46% of the company’s 54.94M shares outstanding.
It has a market capitalization of $348.57M and a beta (3y monthly) value of 1.57. The earnings-per-share (ttm) stands at -$0.93. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.22% over the week and 8.15% over the month.
Earnings per share for the fiscal year are expected to increase by 31.43%, and 106.41% over the next financial year.
Looking at the support for the CRMD, a number of firms have released research notes about the stock. Rodman & Renshaw stated their Buy rating for the stock in a research note on August 26, 2024, with the firm’s price target at $13. RBC Capital Mkts coverage for the CorMedix Inc (CRMD) stock in a research note released on August 10, 2023 offered a Outperform rating with a price target of $6. Needham was of a view on February 17, 2021 that the stock is Buy, while JMP Securities gave the stock Mkt Outperform rating on September 29, 2020, issuing a price target of $22. Truist on their part issued Buy rating on September 21, 2020.
